New Potential Application For Suba-Itraconazolea In Oncology - Improved Anti-fungal Drug Targets Oncology Market
HalcyGen Pharmaceuticals Limited (ASX: HGN) can confirm that itraconazole, the active ingredient in HalcyGen’s lead drug SUBA-Itraconazoleä, is a potent inhibitor of the proliferation of endothelial cells. These are the key cells involved in tumour-angiogenesis and related growth of tumours.
More: continued here
Filed under: Cancer on June 12th, 2008